Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus STERI STAT.
HYDELTRASOL vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid